Opko Health
About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Employees: 2,997
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
490% more call options, than puts
Call options by funds: $5.14M | Put options by funds: $870K
79% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 24
38% more capital invested
Capital invested by funds: $290M [Q4 2024] → $401M (+$110M) [Q1 2025]
36% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 56
8% more funds holding
Funds holding: 232 [Q4 2024] → 250 (+18) [Q1 2025]
7.03% more ownership
Funds ownership: 28.94% [Q4 2024] → 35.97% (+7.03%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2.25
67%
upside
Avg. target
$2.25
67%
upside
High target
$2.25
67%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Barrington Research Michael Petusky | 67%upside $2.25 | Outperform Maintained | 1 May 2025 |
Financial journalist opinion
Based on 3 articles about OPK published over the past 30 days
Neutral
PRNewsWire
1 week ago
NextPlat Issues Interim CEO Update Shareholder Letter
COCONUT GROVE, Fla. , June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter: To Our Shareholders: As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward.
Neutral
GlobeNewsWire
2 weeks ago
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative.
Neutral
Zacks Investment Research
4 weeks ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
Neutral
GlobeNewsWire
1 month ago
OPKO Health to Participate in Two Upcoming Investor Conferences
MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3 rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City.
Neutral
Zacks Investment Research
2 months ago
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
Neutral
Seeking Alpha
2 months ago
OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H. C. Wainwright & Co., LLC Jeffrey Cohen - Ladenburg Thalmann Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Michael Petusky - Barrington Research Operator Good afternoon, and welcome to the OPKO Health First Quarter 2025 Financial Results Conference Call.
Positive
Zacks Investment Research
2 months ago
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 months ago
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago.
Positive
Zacks Investment Research
2 months ago
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround
OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
3 months ago
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.
Charts implemented using Lightweight Charts™